Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D, Valdez T, Dasgupta A, Zhang Y, Yan Y, Komatsubara KM, Chung WP, Ma F, Dai MS
- DOI
- 10.1038/s41591-024-03269-z
- Record issued
- 2026-08-16
- Engine
- 7.39.0
- Exported
- 2026-09-22
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/29a0d78f-4e91-40b8-917d-58b4a9029933 is authoritative.
How this rating was calculated
Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted randomized phase 3 trial with clear scientific premise, rigorous design, and transparent reporting. The main weaknesses are minor: lack of explicit CONSORT adherence statement and a few copyedit issues.
Both reviewers classified the study as interventional and agreed on all dimensions. The statistics verification recomputed only 2 tests (HR with CI) and found them consistent; this is a limited check and does not constitute a full validation of all statistics. The citation check found no retracted or non-existent references.
Numerical inconsistencies
None foundValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
Checked — nothing surfaced.
Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.
- CONSISTENTreported p = .003 · recomputed p = .002Reviewers 1, 2PFS hazard ratio p-value from HR and 95% CI
“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”
Taken as given: The HR is a ratio (log=1).; The CI is a 95% confidence interval.Method: Two-sided p-value derived from the log HR and its 95% CI using a normal approximation.How we recomputed it: pCI(0.67, 0.52, 0.87, 1) - CONSISTENTreported p = .006 · recomputed p = .005Reviewers 1, 2OS hazard ratio p-value from HR and 95% CI
“HR of 0.64, 95% CI 0.47 to 0.88; P = 0.0061”
Taken as given: The HR is a ratio (log=1).; The CI is a 95% confidence interval.Method: Two-sided p-value derived from the log HR and its 95% CI using a normal approximation.How we recomputed it: pCI(0.64, 0.47, 0.88, 1)
Overstated conclusions
None foundConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
Checked — nothing surfaced.
4 major claims checked against the paper's own evidence: all adequately supported.
- supportedReviewers 1, 2SG significantly improved PFS versus chemotherapy in Asian patients with HR+ HER2- mBC.The primary endpoint PFS per BICR was met with HR 0.67, 95% CI 0.52-0.87, P=0.0028, directly supporting the claim.Evidence: Primary endpoint PFS per BICR: HR 0.67, 95% CI 0.52-0.87, P=0.0028.
“PFS was improved with SG versus chemotherapy (hazard ratio of 0.67, 95% confidence interval 0.52–0.87; P = 0.0028; median 4.3 versus 4.2 months).”
AbstractFind in source - supportedReviewers 1, 2SG significantly improved OS versus chemotherapy.OS was improved with HR 0.64, 95% CI 0.47-0.88, P=0.0061, supporting the claim.Evidence: OS: HR 0.64, 95% CI 0.47-0.88, P=0.0061.
“OS also improved with SG versus chemotherapy (hazard ratio of 0.64, 95% confidence interval 0.47–0.88; P = 0.0061; median 21.0 versus 15.3 months).”
AbstractFind in source - supportedReviewers 1, 2SG has a manageable safety profile consistent with prior studies.Safety data show expected TEAEs and no new signals, consistent with prior studies.Evidence: Safety summary in Table 3 and discussion of consistency with prior studies.
“SG demonstrated significant and clinically meaningful improvement in PFS and OS versus chemotherapy, with a manageable safety profile consistent with prior studies.”
AbstractFind in source - supportedReviewers 1, 2SG represents a promising treatment option for Asian patients with HR+ HER2- mBC.The efficacy and safety results support this conclusion, though 'promising' is a reasonable interpretation.Evidence: Efficacy and safety results from the trial.
“SG represents a promising treatment option for Asian patients with HR + HER2 − mBC”
AbstractFind in source
Efficacy claim is anchored to an adequate endpoint and a meaningful effect.
- ADEQUATESurrogate endpointThe primary endpoint is progression-free survival (PFS), which is a clinical outcome, not a surrogate. The paper also reports overall survival (OS) as a secondary endpoint. Both are hard clinical outcomes.
“The primary endpoint was met: PFS was improved with SG versus chemotherapy (hazard ratio of 0.67, 95% confidence interval 0.52–0.87; P = 0.0028; median 4.3 versus 4.2 months). OS also improved with SG versus chemotherapy (hazard ratio of 0.64, 95% confidence interval 0.47–0.88; P = 0.0061; median 21.0 versus 15.3 months).”
- ADEQUATEEffect sizeThe effect sizes are reported as hazard ratios and median survival differences. For PFS, the median difference is small (0.1 months), but the hazard ratio is 0.67 and the authors note that the curves separate later, with landmark analyses showing higher PFS rates at 6 and 12 months. For OS, the median difference is 5.7 months (21.0 vs 15.3), which is clinically meaningful. The authors explicitly state 'clinically meaningful improvement in OS'.
“SG demonstrated significant and clinically meaningful improvement in PFS and OS versus chemotherapy, with a manageable safety profile consistent with prior studies.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites prior work (TROPiCS-02) and notes its limitation of few Asian patients, providing a clear rationale for the study. The premise is well-established and the hypothesis follows logically.
“TROPiCS-02 primarily enrolled non-Asian patients, with Asian patients making up 3% of the study population . Thus, the benefit–risk profile for SG in Asian patients with HR + HER2 − mBC has not been adequately characterized.”
Randomization method (stratified blocked, block size 4) and unit (patient) are described. Blinding is open-label with a stated limitation. Power analysis is provided. Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT and safety populations. Controls are the chemotherapy arm. Independent replication is not applicable for a single pivotal trial.
“Patients were randomized via an interactive web-based response system. The randomization list was generated by a designated vendor using stratified blocked randomization with a block size of four.”
“Assuming an HR of 0.70 (median 5.3 versus 3.7 months), approximately 250 PFS events were needed to detect a statistically significant difference between the two groups at a two-sided 0.05 significance level and 80% power.”
“One potential limitation of this study is the open-label design.”
“The randomization list was generated by a designated vendor using stratified blocked randomization with a block size of four.”
“Assuming an HR of 0.70 (median 5.3 versus 3.7 months), approximately 250 PFS events were needed to detect a statistically significant difference between the two groups at a two-sided 0.05 significance level and 80% power.”
“One potential limitation of this study is the open-label design.”
Sex is reported (mostly female, with 2 male in chemotherapy). Age is reported. Demographics include region, ECOG PS, visceral metastases, prior therapies. Sex justification is not applicable as both sexes are enrolled. Species/strain/housing are not applicable.
“Female | 166 (100) | 163 (99) | | Male | 0 | 2 (1) | | Median age (range), years | 53 (32–72) | 51 (28–79)”
“Female | 166 (100) | 163 (99)”
“Median age (range), years | 53 (32–72) | 51 (28–79)”
The ethics statement names the Declaration of Helsinki and ICH-GCP, and states approval by national regulatory authorities and each site's ethics committee. A list of approving sites is provided. Written informed consent is stated. Regulatory compliance is adequate.
“EVER-132-002 was compliant with Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines and was approved by national regulatory authorities, as well as each investigational sites’ ethics committee or review board.”
“All patients gave written informed consent.”
“EVER-132-002 was compliant with Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines and was approved by national regulatory authorities, as well as each investigational sites’ ethics committee or review board.”
“All patients gave written informed consent.”
SG is identified as sacituzumab govitecan with dose and schedule. Chemotherapy options are named. Statistical software (SAS version 9.4) is identified. No antibodies, cell lines, or mycoplasma testing are applicable.
“SG (10 mg kg −1 intravenously days 1 and 8 of every 3 week cycle)”
“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”
“All statistical analyses were performed using SAS (SAS Institute, version 9.4 or later, SAS Institute).”
Tests named include stratified log-rank, Cox proportional hazards, Cochran-Mantel-Haenszel. Exact p-values are given (e.g., P=0.0028). Effect sizes with 95% CIs are reported. Data presentation includes Kaplan-Meier curves and tables with n. Mathematical plausibility checks were not performed due to lack of raw data; no errors found.
“P = 0.0028; median 4.3 versus 4.2 months”
“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”
“HR of 0.67, 95% CI 0.52 to 0.87; P = 0.0028”
“Comparisons of PFS and OS between the treatment groups were performed using a stratified log-rank test (with the three stratification factors used during randomization).”
The data availability statement describes a managed-access process via Gilead with conditions and contact email. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.
“Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting nonconflict of interest.”
“To protect the privacy of study participants and proprietary information, Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers based on submitted curriculum vitae and reflecting nonconflict of interest.”
Trial registration number is provided (NCT04639986). Methods are detailed. Limitations are discussed (open-label, small subgroups). Conclusions are proportional to the evidence. Funding (Gilead) and competing interests are disclosed. Reporting guideline is not explicitly mentioned but the paper includes a reporting summary.
“ClinicalTrials.gov identifier no. NCT04639986”
“One potential limitation of this study is the open-label design.”
“This study is sponsored by Gilead Sciences, Inc.”
“ClinicalTrials.gov identifier no. NCT04639986”
“One potential limitation of this study is the open-label design.”
Registered (2 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 33 references by DOI: 24 verified — 9 no DOI (shown, not verified).
- NO DOIGlobal Cancer Observatory, GLOBOCAN 2022, World fact sheetNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGlobal Cancer Observatory, GLOBOCAN 2022, China fact sheetNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGlobal Cancer Observatory, GLOBOCAN 2022, Republic of Korea fact sheetNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIncidence and mortality rates for the top 10 cancers in TaiwanNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOICancer stat facts: female breast cancer subtypesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer, version 1.2024No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIn vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancerNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITrodelvy (sacituzumab govitecan-hziy) [prescribing information]No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITrodelvy [summary of product characteristics]No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttps://clinicaltrials.gov/ct2/show/NCT04639986?term=NCT04639986LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT03901339LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly consistency, clarity.
- MINORconsistencyAbstract“HR + HER2 − ) metastatic BC (mBC)”→ Remove stray parenthesis: 'HR + HER2 − metastatic BC (mBC)'Typographical error in the abstract.
- MINORclarityResults, Patient characteristics“Of the 485 patients screened between 9 December 2020 and 2 December 2022, 331 were randomized”→ Consider adding 'at 41 study sites' to the sentence for clarity.Minor clarity improvement.
- MINORconsistencyTable 1 footnote b“Summary of prior CDK4/6i duration accounted for the three patients who were mis-stratified for the stratification factor ‘prior CDK4/6i in metastatic setting’.”→ Clarify the sentence for readability.The sentence is grammatically awkward.
- MINORclarityDiscussion, paragraph 2“The median PFS values were similar between SG (4.3 months) and chemotherapy (4.2 months) due to a convergence of the curves at the median time point and do not reflect the overall benefit that patients in the SG group received as measured by the HR.”→ Consider rephrasing for clarity.The sentence is long and could be split.
The published work is robust and well-reported. An informed reader should weigh the open-label design and the limited statistical verification as minor caveats; no erratum or correction appears warranted based on this audit.
- 1.MEDIUMreportingAdd an explicit statement of adherence to CONSORT guidelines in the Methods or Reporting Summary.The paper currently does not explicitly name a reporting guideline, which is a minor transparency gap.
- 2.MEDIUMreportingInclude a CONSORT flow diagram in the main text or as supplementary material.A flow diagram improves reporting completeness and is expected for a randomized trial.
- 3.MEDIUMdata codeSpecify a timeframe for response to data requests in the data availability statement.Adding a timeline makes the data-sharing route more concrete and actionable.
- 4.MEDIUMstatisticsAdd a brief statement on how missing data were handled (e.g., censoring rules for PFS/OS) in the statistical analysis section.Clarifying censoring and missing data handling enhances reproducibility.
- 5.MEDIUMreportingClarify the role of the sponsor in data analysis and manuscript preparation in the competing interests or acknowledgements.Transparency about sponsor involvement addresses potential conflicts of interest.
- 6.MEDIUMreportingReport the number of patients with missing Trop-2 H-score in the text rather than only in a table footnote.Improves transparency about a key biomarker assessment.
- 7.MEDIUMreportingProvide the statistical analysis plan as supplementary material.Enhances reproducibility and allows readers to verify pre-specified analyses.
- 8.LOWcopyeditFix the stray parenthesis in the Abstract: 'HR + HER2 − ) metastatic BC (mBC)' should read 'HR + HER2 − metastatic BC (mBC)'.Typographical error in the abstract.
- 9.LOWcopyeditAdd 'at 41 study sites' to the sentence in Results, Patient characteristics for clarity.Minor clarity improvement.
- 10.LOWcopyeditClarify the sentence in Table 1 footnote b about prior CDK4/6i duration and mis-stratification.The sentence is grammatically awkward and could be misinterpreted.
- 11.LOWcopyeditRephrase the long sentence in Discussion, paragraph 2 about median PFS convergence for clarity.The sentence is long and could be split for readability.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.